nn9500

NN9500 is a code name for a recombinant protein drug under development by Novo Nordisk, primarily as an analogue of fibroblast growth factor 21 (FGF21). It is being investigated for the treatment of non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), and potentially other liver diseases. FGF21 analogues like NN9500 are designed to regulate body fat by increasing the removal of fat from blood, removing fat from the liver, decreasing scarring in the liver, and possibly reducing inflammation. The mechanism involves mimicking or enhancing endogenous FGF21 activity to improve metabolic parameters and reduce hepatic damage. Clinical trials have evaluated NN9500 both alone and in combination with semaglutide (a GLP-1 receptor agonist) to assess efficacy in reducing liver damage associated with NASH[1][4][7].

Other names

zalfermin